뇌졸중 환자의 당뇨병 약물 요법

키워드

참고문헌 (45)

1. "Stroke fact sheet in Korea 2018" (2018)[URL]
2. "Diabetes fact sheet in Korea 2018" (2018)[URL]
3. Azimova K, "Cardiovascular safety profile of currently available diabetic drugs", Ochsner J, 14, pp.616~632 (2014)
4. Emerging Risk Factors Collaboration, "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease : a collaborative meta-analysis of 102 prospective studies", Lancet, 375, pp.2215~2222 (2010)
5. Kernan WN, "Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2014, pp.45, 2160~2236
6. UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", Lancet, 352, pp.837~853 (1998)
7. Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications insulin-dependent diabetes mellitus", N Engl J Med, 329, pp.977~986 (1993)
8. Action to Control Cardiovascular Risk in Diabetes Study Group, "Effects of intensive glucose lowering in type 2 diabetes", N Engl J Med, 358, pp.2545~2559 (2008)
9. ADVANCE Collaborative Group, "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes", N Engl J Med, 358, pp.2560~2572 (2008)
10. Duckworth W, "Glucose control and vascular complications in veterans with type 2 diabetes", N Engl J Med, 360, pp.129~139 (2009)
11. Holman RR, "10-year follow-up of intensive glucose control in type 2 diabetes", N Engl J Med, 359, pp.1577~1589 (2008)
12. Bailey CJ, "Metformin", N Engl J Med, 334, pp.574~579 (1996)
13. "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group", Lancet, 352, pp.854~865 (1998)
14. Li J, "Effects of metformin in experimental stroke", Stroke, 41, pp.2645~2652 (2010)
15. Davies MJ, "Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)", Diabetes Care, 41, pp.2669~2701 (2018)
16. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, "Pharmacologic management of type 2 diabetes", Can J Diabetes, 37, pp.S61~S68 (2013)
17. Aguilar-Bryan L, "Cloning the beta cell high-affinity sulfonylurea receptor : a regulator of insulin secretion", Science, 268, pp.423~426 (1995)
18. Quast U, "The impact of ATP-sensitive K+channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium", Diabetes, 53, pp.156~164 (2004)
19. Stephan D, "Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP)channels", Diabetologia, 49, pp.2039~2048 (2006)
20. Sun HS, "Neuronal K(ATP)channels mediate hypoxic preconditioning and reduce subsequent neonatal hypoxic-ischemic brain injury", Exp Neurol, 263, pp.161~171 (2015)
21. Kunte H, "Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke", Stroke, 38, pp.2526~2530 (2007)
22. Weih M, "Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes", Stroke, 32, pp.2029~2032 (2001)
23. Bannister CA, "Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls", Diabetes Obes Metab, 16, pp.1165~1173 (2014)
24. Liu R, "Cerebrovascular safety of sulfonylureas : the role of K ATP channels in neuroprotection and the risk of stroke in patients with type 2 diabetes", Diabetes, 65, pp.2795~2809 (2016)
25. Yki-Jarvinen H, "Thiazolidinediones", N Engl J Med, 351, pp.1106~1118 (2004)
26. Kahn SE, "Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy", N Engl J Med, 355, pp.2427~2443 (2006)
27. Dormandy JA, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial", Lancet, 366, pp.1279~1289 (2005)
28. Wilcox R, "Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke : results from PROactive(PROspective pioglitAzone Clinical Trial In macroVascular Events 04)", Stroke, 38, pp.865~873 (2007)
29. Kernan WN, "Pioglitazone after ischemic stroke or transient ischemic attack", N Engl J Med, 374, pp.1321~1331 (2016)
30. Kernan WN, "Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke", Neurology, 60, pp.1447~1451 (2003)
31. Kernan WN, "Insulin resistance and risk for stroke", Neurology, 59, pp.809~815 (2002)
32. Lewis JD, "Risk of bladder cancer among diabetic patients treated with pioglitazone : interim report of a longitudinal cohort study", Diabetes Care, 34, pp.916~922 (2011)
33. Nauck MA, "The incretin effect in healthy individuals and those with type 2 diabetes : physiology, pathophysiology, and response to therapeutic interventions", Lancet Diabetes Endocrinol, 4, pp.525~536 (2016)
34. Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)
35. Zannad F, "Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE : a multicentre, randomised, double-blind trial", Lancet, 385, pp.2067~2076 (2015)
36. Green JB, "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 373, pp.232~242 (2015)
37. Rosenstock J, "Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk : the CARMELINA randomized clinical trial", JAMA, 321, pp.69~79 (2019)
38. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
39. Neal B, "Canagliflozin and cardiovascular and renal events in type 2diabetes", N Engl J Med, 377, pp.644~657 (2017)
40. Wiviott SD, "Dapagliflozin and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 380, pp.347~357 (2019)
41. Wu JH, "Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes : a systematic review and meta-analysis", Lancet Diabetes Endocrinol, 4, pp.411~419 (2016)
42. Marso SP, "Liraglutide and cardiovascular outcomes in type 2diabetes", N Engl J Med, 375, pp.311~322 (2016)
43. Marso SP, "Semaglutide and cardiovascular outcomes in patients with type 2diabetes", N Engl J Med, 375, pp.1834~1844 (2016)
44. ORIGIN Trial Investigators, "Basal insulin and cardiovascular and other outcomes in dysglycemia", N Engl J Med, 367, pp.319~328 (2012)
45. 고승현, "Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association", Diabetes and Metabolism Journal, 41(5), pp.337~348 (2017), 대한당뇨병학회[DOI]

관련 논문AI추천